Amalgamated Financial’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Amalgamated Financial’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$44K	Buy	+5,782	New	+$54.8K	﹤0.01%	2487

Other funds holding GTHX

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Amalgamated Financial's GTHX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2022: 5,782 shares worth $44K. The stake represents ﹤0.01% of the portfolio and ranks #2487 among its holdings.

115 funds tracked by Wall St. Rank hold GTHX as of Q1 2022.

Amalgamated Financial held 5,782 shares of G1 Therapeutics, Inc. Common Stock worth $44K as of Q1 2022.
G1 Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
G1 Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2487 holding.
115 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.